Anthony J. Polverino - 07 Jan 2022 Form 4 Insider Report for Zymeworks Inc.

Reporting relationship: Chief Scientific Officer
Issuer ticker: N/A
Reported as of: 07 Jan 2022
Net transaction value: +$1,032
SEC form: 4
Accepted by SEC: 07 Jan 2022, 20:30:34 UTC
Prior SEC filing: 17 Dec 2021
Next SEC filing: 03 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Anthony J. Polverino filed Form 4 for Zymeworks Inc. on 07 Jan 2022.

Key facts

This page summarizes Anthony J. Polverino's Form 4 filing for Zymeworks Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Jan 2022, 20:30.

Change

Previous filing in this sequence was filed on 17 Dec 2021.
Current net transaction value: +$1,032.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZYME transaction

Common Shares

Award

Transaction value: $1,032
Shares: +74
Change %: +0.2%
Price: $13.94^*
Shares after: 36,407
Date: 07 Jan 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on December 31, 2021.